EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Apures Co's enterprise value is ₩22,656.5 Mil.
Apures Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-3,401.7 Mil. Therefore, Apures Co's EV-to-EBITDA for today is -6.66.
The historical rank and industry rank for Apures Co's EV-to-EBITDA or its related term are showing as below:
XKRX:149300'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -138.33 Med: -10.17 Max: -5.5
Current: -6.66
During the past 10 years, the highest EV-to-EBITDA of Apures Co was -5.50. The lowest was -138.33. And the median was -10.17.
XKRX:149300's EV-to-EBITDA is ranked worse than 100% of 108
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.15
vs XKRX:149300: -6.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-09), Apures Co's stock price is ₩400.00.
Apures Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-133.000. Therefore, Apures Co's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Apures Co EV-to-EBITDA Historical Data
The historical data trend for Apures Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apures Co's EV-to-EBITDA
For the Diagnostics & Research subindustry, Apures Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apures Co's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Apures Co's EV-to-EBITDA falls into.
Apures Co EV-to-EBITDA Calculation
Apures Co's EV-to-EBITDA for today is calculated as:
Apures Co's current Enterprise Value is ₩22,656.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apures Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-3,401.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apures Co (XKRX:149300) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Apures Co's share price for today is ₩400.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apures Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-133.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Apures Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:149300 has been successfully added to your 